NCT02077257View on ClinicalTrials.gov

LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients

PHASE4UnknownINTERVENTIONAL
Enrollment

1,060

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

May 31, 2016

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Rosuvastatin

Rosuvastatin 20 mg/d compared to 10 mg/day

Trial Locations (1)

Unknown

RECRUITING

Beijing Anzhen Hospital, Beijing

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Committee of Cardio-Cerebral-Vascular Diseases of GSC

OTHER